• employee- and consultant-related expenses, which will include salaries, benefits and stock-based compensation, and certain consultant fees and travel expenses;

filing / Jul 29, 2026 / receipt

In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures.

filing / Jul 29, 2026 / receipt

and stock-based compensation for research and development personnel, external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations, facilities costs, travel costs, dues and subscriptions, depreciation and materials used in preclinical studies, clinical trials and research and development.

filing / Jul 29, 2026 / receipt

If we expand our presence outside of the United States, we will be required to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

filing / Jul 29, 2026 / receipt

These demands also may require the hiring of additional senior management personnel or the development of additional expertise by our senior management personnel.

filing / Jul 29, 2026 / receipt

One of our subsidiaries is located in Ireland and another is located in Australia and we may further expand our international operations.

filing / Jul 29, 2026 / receipt

• employee- and consultant-related expenses, which will include salaries, benefits and stock-based compensation, and certain consultant fees and travel expenses;

filing / Apr 30, 2026 / receipt

In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures.

filing / Apr 30, 2026 / receipt

and stock-based compensation for research and development personnel, external research and development expenses incurred pursuant to agreements with third-party manufacturing organizations, facilities costs, travel costs, dues and subscriptions, depreciation and materials used in preclinical studies, clinical trials and research and development.

filing / Apr 30, 2026 / receipt

If we expand our presence outside of the United States, we will be required to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

filing / Apr 30, 2026 / receipt

These demands also may require the hiring of additional senior management personnel or the development of additional expertise by our senior management personnel.

filing / Apr 30, 2026 / receipt

One of our subsidiaries is located in Ireland and another is located in Australia and we may further expand our international operations.

filing / Apr 30, 2026 / receipt